Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women

Molecular and Cellular Biochemistry

Volumn 261, Issue 1, 2004, Pages 71-75

  Piperi, Christina ^a   Kalofoutis, Christos ^a   Lagogianni, Irene ^a   Troupis, George ^a   Kalofoutis, Anastasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atorvastatin; Cholesterol; HDL; LDL; Phospholipids; Post menopausal women; Raloxifene; Serum lipids; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPID COMPOSITION; MAJOR CLINICAL STUDY; NORMAL HUMAN; PHOSPHOLIPID BLOOD LEVEL; POSTMENOPAUSE; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPID METABOLISM; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; PYRROLES; RALOXIFENE;

EID: 3442885672     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000028739.10079.0b     Document Type: Article

References (31)

1. Kannel WB, Hjortland MC, McNamara PM, Gordon T: Menopause and risk of cardiovascular disease: The Framingham Study. Ann Inter Med 85: 447-452, 1976
2. Colditz GA, Willett WC, Stampfer MJ, Rosner BS, Speizer FE, Hennekens CH: Menopause and the risk of coronary heart disease in women. N Engl J Med 316: 1105-1110, 1987
3. Bryant HU, Dere WH: Selective estrogen receptor modulators: An alternative to hormone replacement therapy. Proc Soc Exp Biol Med 217: 45-52, 1998
4. Umland EM, Rinaldi C, Parks SM, Boyce EG: The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann Pharmacother 33: 1315-1328, 1999
5. Agnusdei D, Liu-Leage S, Augendre-Ferrante B: Results of international clinical trials with raloxifene. Ann Endocrinol 60: 242-246, 1999
6. Kauffman RF, Bryant HU: Selective estrogen receptor modulators. Drugs New Perspect 8: 531-539, 1995
7. Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an oestrogen response element activated by metabolites of 17b-estradiol and raloxifene. Science 273: 1222-1225, 1996
8. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL: Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Min Res 13: 1747-1754, 1998
9. Park L, Evans MF: Raloxifene: Designer estrogen for preventing postmenopausal osteoporosis. Can Fam Phys 45: 1191-1193, 1999
10. Draper MW, Flowers DE, Huster WJ, Neild JA: Effects of raloxifene (LY139481) HC1 on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. In: C. Christiansen and B. Riis (eds). Proceedings 1993: Fourth International Symposium on Osteoporosis and Consensus Development Conference, Handelstrykkeriet Aalborg ApS, Aalborg, Denmark, 1993, pp. 119-121
11. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud CA: Controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Min Res 11: 835-842, 1996
12. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 279: 1445-1451, 1998
13. Boyack M, Lookinland S, Chasson S: Efficacy of raloxifene for treatment of menopause: A systematic review. J Am Acad Nurse Pract 14: 150-165, 2002
14. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622, 1998
15. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97: 1453-1460, 1998
16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009, 1996
17. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995
18. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164: 361-369, 2002
19. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ: Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43: 1701-1707, 2002
20. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158: 407-416, 2001
21. Hunninghake D, Insull W, Knopp R, Davidson M, Lohrbauer L, Jones P, Kafonek S: Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol 88: 635-639, 2001
22. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, Thillet J: Atorvastatin lowers lipoprotein (a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 164: 305-311, 2002
23. Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M: Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150: 121-127, 2000
24. Friedewald WT, Levy RI, Fredrickso S: Estimation of the concentration of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972
25. Yamaguchi Y: Determination of high-density lipoprotein phospholipids in serum. Clin Chim Acta 26: 1275-1277, 1980
26. Insull W, Kafonek S, Goldner D, Zieve F, for the ASSET Investigators: Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. Am J Cardiol 87: 554-559, 2001
27. Schweitzer M, Tessier D, Vlahos WD, Leite L, Collet JP, McQueen MJ, Harvey L, Alaupovic P: A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 162: 201-210, 2002
28. Giral P, Bruckert E, Jacob N, Chapman MJ, Foglietti MJ, Turpin G: Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154: 421-427, 2001
29. Kakafika A, Tsimihodimos V, Elisaf M: Effect of atorvastatin on serum uric acid levels. Atherosclerosis 158: 255, 2001
30. Kakafika A, Liamis G, Elisaf M, Mikhailidis D: Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 17: 230-231, 2001
31. Rosenson RS, Tangney CC: Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279: 1643-1650, 1998